APUS
Apimeds Pharmaceuticals US, Inc.
APUS
APUS
5 hedge funds and large institutions have $50.2K invested in Apimeds Pharmaceuticals US, Inc. in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
–
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$23.5K |
| 2 |
Goldman Sachs
New York
|
+$21.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.55K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$52 |
| 5 |
JPMorgan Chase & Co
New York
|
+$9 |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $23.5K | +$23.5K | +13,359 | New |
|
|
2
Goldman Sachs
New York
| $21.1K | +$21.1K | +11,987 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $5.55K | +$5.55K | +3,151 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $52 | +$52 | +29 | New |
|
|
5
JPMorgan Chase & Co
New York
| $9 | +$9 | +5 | New |
|